AEON

AEON Biopharma, Inc. (AEON) - Q3 2024 10-Q Summary

Business Context and Reporting Period

This report covers the quarterly period ended September 30, 2024. AEON Biopharma, Inc. is a clinical-stage biopharmaceutical company focused on developing ABP-450 (prabotulinumtoxinA). Following a merger with Priveterra Acquisition Corp. in July 2023, the company operates as a "Successor" entity. The company is currently classified as a non-accelerated filer, smaller reporting company, and emerging growth company.

Key Financial Metrics

Note: YTD 2024 Net Income of $40.0 million is primarily driven by a non-cash gain of $97.5 million from the change in fair value of contingent consideration, offset by operating losses and other fair value adjustments.

Material Changes vs. Prior Period

• Strategic Pivot: In May 2024, the company discontinued Phase 2 clinical trials for episodic and chronic migraine after failing to meet primary endpoints. In July 2024, management announced a strategic reprioritization to pursue a Section 351(k) biosimilar regulatory pathway for ABP-450, using Botox as the reference product.
• Expense Reduction: Operating expenses decreased significantly compared to prior periods due to the wind-down of clinical trials and headcount reductions. R&D expenses for the three months ended September 30, 2024, were $1.0 million, an 88% decrease from the comparable period in 2023.
• Debt Financing: The company issued $15.0 million in senior secured convertible notes to Daewoong Pharmaceutical Co., LTD. in March and April 2024. These notes accrue interest at 15.79% annually.
• Forward Purchase Agreements: The company terminated Forward Purchase Agreements (FPAs) with ACM and Polar in March 2024. The company recorded a charge of $20.3 million for the nine months ended September 30, 2024, to reverse related subscription receivables and derivative liabilities.

Outlook, Risks, and Management Commentary

• Going Concern Warning: Management has concluded there is substantial doubt about the company's ability to continue as a going concern. As of September 30, 2024, cash balances were only $0.5 million. The company expects to have sufficient cash to fund operations only into the fourth quarter of 2024.
• Capital Needs: Further development of the biosimilar pathway and any additional studies will require significant additional funding. The company is actively seeking equity or debt financing but cannot assure success.
• Regulatory Path: The company held an initial meeting with the FDA in Q3 2024 to align on next steps for the Botox biosimilar. Comparative analytic studies are anticipated to commence in Q4 2024, with a potential Biosimilar Biological Product Development (BPD) meeting in 2025.
• Internal Controls: The company disclosed material weaknesses in internal control over financial reporting, specifically regarding risk assessment of complex transactions and valuation of financial instruments, which led to prior restatements.
• Legal Proceedings: Odeon Capital Group LLC filed a lawsuit in September 2023 alleging non-payment of a $1.25 million deferred underwriting fee. The company successfully moved to dismiss certain claims in November 2023.

Investor Verification Checklist

• Liquidity Runway: Verify the company's ability to secure financing before Q4 2024 ends, given the $0.5 million cash balance and substantial doubt disclosure.
• Convertible Note Terms: Review the specific conversion triggers and interest rates (15.79%) of the $15 million Daewoong notes, including the "Termination Purchase Right" if commercialization ceases.
• Biosimilar Strategy Viability: Assess the feasibility and timeline of the new Section 351(k) biosimilar pathway compared to the failed original BLA strategy.
• Contingent Consideration: Monitor the $6.9 million contingent consideration liability, which is highly sensitive to stock price and milestone probabilities.
• Internal Control Remediation: Track progress on remediation of material weaknesses in financial reporting to ensure future data reliability.